Skip to content

COMPARISON BETWEEN DIFFERENT DOSES OF A LOCAL ANESTHETIC AGENT IN CONTROLLING ETOMIDATE INDUCED MUSCLE DISORDER

STUDY OF EFFICACY OF DIFFERENT DOSES OF LIGNOCAINE HYDROCHLORIDE IN ATTENUATING ETOMIDATE INDUCED MYOCLONUS: A RANDOMIZED CONTROLLED STUDY.

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/02/017653
Enrollment
150
Registered
2019-02-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: LIGNOCAINE HYDROCHLORIDE: 1 MILIGRAM/KG BODY WEIGHT DILUTED UPTO 6 ML BY ADDING NORMAL SALINE TO BE ADMINISTERED INTRAVENOUSLY Intervention2: LIGNOCAINE HYDROCHLORIDE: 1.5 MILIGRAM/KG B

Sponsors

INDIRA GANDHI INSTITUTE OF MEDICAL SCIENCES PATNA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.PATIENT OF ASA PHYSICAL STATUS 1 AND 2 2.PATIENTS BETWEEN 20 TO 60 YEARS OF AGE OF EITHER SEX. 3.PATIENTS WILLING TO PARTICIPATE. 4.PATIENTS SCHEDULED TO UNDERGO ELECTIVE SURGERIES UNDER PLANNED GENERAL ANAESTHESIA

Exclusion criteria

Exclusion criteria: 1.PATIENTS REFUSAL TO PARTICIPATE. 2.PATIENTS WITH KNOWN SENSITIVITY TO LIGNOCAINE AND ETOMIDATE. 3.ANTICIPATED DIFFICULT AIRWAY. 4.PREGNANT OR LACTATING FEMALES. 5.IMPAIRED RENAL AND HEPATIC DYSFUNCTION. 6.KNOWN ADRENAL DYSFUNCTION. 7.PSYCHOLOGICAL OR NEUROLOGICAL ABNORMALITIES. 8.CARDIAC CONDUCTION ABNORMALITIES. 9.PATIENTS ON ANTIARRHYTHMIC MEDICATIONS.

Design outcomes

Primary

MeasureTime frame
INCIDENCE OF MYOCLONUSTimepoint: 1 MINUTE, 2 MINUTES

Secondary

MeasureTime frame
SEVERITY OF MYOCLONUS AND ANY OTHER ADVERSE EFFECTSTimepoint: 1 MINUTE, 2 MINUTES

Countries

India

Contacts

Public ContactSWATI SHIROMANI

INDIRA GANDHI INSTITUTE OF MEDICAL SCIENCES, PATNA.

AJPTA_IGIMS@YAHOO.CO.UK9473191810

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026